Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is identified as a promising investment opportunity in the biotech sector, with a recent price target adjustment by Deutsche Bank to $30 from $31, maintaining a Hold rating post Q4 fiscal report [1]. Financial Performance - For Q4 2025, Harmony Biosciences reported revenue of $243.8 million, reflecting a 21% year-over-year growth for its product WAKIX. The full-year net product revenue reached $868.5 million, showcasing six consecutive years of revenue growth and profitability [2]. - The company anticipates that WAKIX will exceed $1 billion in revenue and achieve blockbuster status by 2026, indicating strong market potential for the product [3]. Product and Market Position - WAKIX is a therapeutic product developed by Harmony Biosciences that enhances histamine signaling in the brain by binding to H3 receptors, aimed at treating neurological disorders [4]. - The average number of patients using WAKIX increased by approximately 400 to around 8,500 in fiscal Q4 2025, marking the third consecutive quarter of similar patient growth [3].

Core Insights - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is recognized as one of the best investment stocks for 2026, indicating strong future potential in the market [1][2]. Company Developments - Truist Securities downgraded HRMY from Buy to Hold due to concerns raised during a patent trial against AET Pharma, suggesting a potential negative outcome for Harmony's case and highlighting risks for the Wakix franchise, with generic competition expected before 2029 [3][8]. - On February 17, the U.S. FDA approved Harmony's supplemental New Drug Application for WAKIX (pitolisant) tablets, allowing treatment for cataplexy in children aged six and older, marking it as the first FDA-approved non-scheduled therapy for narcolepsy [4][5]. Industry Context - Harmony Biosciences focuses on developing therapies for rare neurological disorders, particularly innovative treatments for narcolepsy and other sleep-related diseases, positioning itself within a niche but critical segment of the biopharmaceutical industry [5].

Core Insights - Harmony Biosciences is on track to achieve blockbuster status for its WAKIX product, with projected net revenue of $1.0 billion to $1.04 billion in 2026, marking a significant milestone in the franchise's history [1][4][6] Financial Performance - For the full year, Harmony reported WAKIX net product revenue of $868.5 million, reflecting strong year-over-year growth and extending six consecutive years of revenue growth and profitability [2][4] - In the fourth quarter, the company achieved net product revenue of $243.8 million, up from $201.3 million in the prior-year period, driven by strong demand for WAKIX [3][6] - The company ended the quarter with $882.5 million in cash, cash equivalents, and investments, with $348.2 million generated from operations in 2025 [18] Product and Pipeline Developments - Harmony is advancing multiple lifecycle and pipeline programs, including pitolisant GR and pitolisant HD, with regulatory submissions planned for 2026 and 2028 respectively [5][12][13] - The company has received FDA approval for WAKIX for pediatric patients with narcolepsy, expanding its market reach [8] - Ongoing Phase 3 programs for EPX-100 in epilepsy are expected to yield top-line data in 2027, with potential PDUFA in 2028 [17] Market Strategy and Growth Initiatives - The company attributes sustained momentum in WAKIX sales to its differentiated profile as a non-scheduled treatment option, strong brand awareness, and effective promotional strategies [7][8] - Harmony plans to expand its field-based teams by nearly 20% to support continued growth, with a significant increase in field reimbursement headcount [8] - Management is focused on lifecycle strategies to extend the pitolisant franchise and is exploring new formulations for broader CNS indications [14][15] Intellectual Property and Litigation - Harmony has settled with six of seven ANDA filers, with generic entry expected no sooner than March 2030 if pediatric exclusivity is granted [9][10] - The company remains confident in its intellectual property and is actively defending it against ongoing litigation [11]

Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in the same period last year, marking the highest quarterly revenues to date [4][23] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [5] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [24] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching approximately 8,500 average patients on WAKIX [4][10] - The approval of WAKIX for the treatment of cataplexy in pediatric patients aged six years and older is expected to enhance market penetration [12] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for continued growth of WAKIX [5] - The company anticipates WAKIX net revenue to reach blockbuster status of $1 billion-$1.04 billion in 2026, reflecting strong expectations for growth [25] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the next-generation pitolisant formulations, including pitolisant GR and pitolisant HD, targeting unique indications in orphan rare diseases [7][9] - The company is advancing a robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications, aiming for multiple catalysts over the next few years [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, supported by strong commercial execution and a clear growth strategy [9][28] - The company remains committed to defending its intellectual property and is optimistic about the potential for pediatric exclusivity for WAKIX [7][24] Other Important Information - Harmony ended Q4 2025 with approximately $882.5 million in cash equivalents and investments, providing financial flexibility for growth initiatives [23] - The company is expanding its field-based teams by nearly 20% to enhance market presence and support continued growth [11] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the emerging benefit-risk profile for EPX-100? - Management noted that patients in the Dravet syndrome study had treatment-resistant seizures, with a median reduction in seizures of approximately 50% and a favorable safety profile compared to other medications [30][32] Question: What is the timeline for the NDA submission for pitolisant GR? - The company is on track to submit the NDA for pitolisant GR in Q2 2026, with a target PDUFA date in Q1 2027 [52][53] Question: How is the company preparing for the pediatric cataplexy indication? - Management highlighted that the approval for pediatric cataplexy provides greater flexibility for healthcare providers and is expected to enhance the overall market opportunity for WAKIX [90][91] Question: What are the dynamics behind the increase in SG&A expenses in Q4? - The increase in expenses was primarily driven by R&D investments for ongoing Phase 3 studies and litigation-related costs [61][70]

Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in the same period last year, marking the highest quarterly revenues to date [4][23] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [5] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [24] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching approximately 8,500 average patients on WAKIX [4][10] - The company is guiding WAKIX net revenue to blockbuster status of $1 billion-$1.04 billion for 2026, reflecting strong expectations for continued growth [5][25] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for WAKIX [5] - The recent FDA approval of WAKIX for the treatment of cataplexy in pediatric patients aged 6 years and older is expected to enhance market penetration [12] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the next-generation pitolisant formulations, including pitolisant GR and pitolisant HD, targeting unique indications in orphan rare diseases and broader CNS indications [7][9] - The company is advancing a robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications, aiming for multiple catalysts over the next few years [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, supported by strong commercial execution and a clear path for growth [9][28] - The company remains committed to defending its intellectual property and is optimistic about the potential for pediatric exclusivity for WAKIX [7][28] Other Important Information - Harmony ended Q4 2025 with approximately $882.5 million in cash equivalents and investments, providing financial flexibility for growth initiatives [23] - The company is expanding its field-based teams by nearly 20% to enhance market presence and support continued growth [11] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the baseline anti-seizure med use for EPX-100 in Dravet syndrome? - Management noted that patients had treatment-resistant seizures and comparable baseline seizure rates to other studies, with a median reduction in seizures of approximately 50% [30][32] Question: What is the PK, PD, and safety bar for the orexin 2 receptor agonist in phase 1 studies? - Management indicated that they expect to confirm the expected profile of once-daily dosing and are making progress towards advancing the program [38][39] Question: Can you clarify the increase in SG&A expenses in Q4? - The increase was primarily driven by R&D investments for phase 3 studies and litigation expenses related to ANDA settlements [60][62] Question: What is the timeline for decisions expected in ongoing litigation? - Management stated that the timeline for a ruling is uncertain, but they are confident in their position following recent settlements with generic filers [74][76]

Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in Q4 2024, marking the highest quarterly revenues to date [3][22] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [4] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [23] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching about 8,500 average patients on the drug [3][4] - The company anticipates WAKIX net revenue to reach blockbuster status of $1 billion-$1.04 billion in 2026, driven by strong demand and market opportunity [4][10] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for continued growth of WAKIX [4] - The recent FDA approval of WAKIX for treating cataplexy in pediatric patients aged 6 years and older is expected to enhance market penetration [10][95] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the upcoming NDA submission for Pitolisant GR in Q2 2026 and a target PDUFA date in Q1 2027 [5][26] - The company is also exploring broader CNS indications with a new formulation of pitolisant, supported by newly licensed IP with patent protection until 2042 [6][17] - A robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications is in place, setting the stage for multiple catalysts [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, citing strong execution and market demand [4][26] - The company is well-positioned with a strong balance sheet, approximately $882.5 million in cash equivalents, to fund growth and pipeline advancements [22][24] Other Important Information - The company has settled with six of the seven ANDA filers regarding WAKIX, with generic entry not expected before March 2030 if pediatric exclusivity is granted [5][50] - Significant increases in R&D investments are anticipated as the company advances its pipeline, with five registrational studies ongoing and a sixth planned [25][63] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the emerging benefit-risk profile for EPX-100? - Management noted that patients in the Dravet syndrome study had treatment-resistant seizures, with a median reduction in seizures of approximately 50% and a favorable safety profile compared to other medications [30][32] Question: What is the PK, PD, and safety bar for the orexin 2 receptor agonist? - Management indicated that they expect to see clinical PK data by mid-2026 and are making progress towards advancing the program to the next stage of development [39][41] Question: Can you clarify the increase in SG&A expenses in Q4? - The increase was primarily driven by R&D investments for Phase 3 studies and litigation expenses related to ANDA settlements [62][63] Question: What is the timeline for decisions regarding ongoing litigation? - Management stated that the timeline for a ruling is uncertain, but they remain confident in their IP strength and the settlements achieved with generic filers [78][79]

Q4 & FY 2025 Financial Results & Business Update February 24, 2026 Copyright © 2026 Harmony Biosciences. All rights reserved. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations ...

Financial Performance - WAKIX (pitolisant) generated net product revenue of $868.5 million for the year ended December 31, 2025, with an average of approximately 8,500 patients on the treatment in Q4 2025[25]. - Three customers accounted for 100% of gross product revenue for the year ended December 31, 2025, with Caremark LLC at 38%, Accredo Health Group, Inc. at 36%, and PANTHERx Specialty Pharmacy LLC at 26%[54]. - The company is substantially dependent on the commercial success of its only approved product, WAKIX, which was approved for treating excessive daytime sleepiness (EDS) in adult patients with narcolepsy in August 2019 and for cataplexy in October 2020[145]. - The company's revenue from WAKIX is influenced by market size, competition, pricing acceptance, and reimbursement capabilities[147]. - The company expects WAKIX sales to generate substantially all revenue for the foreseeable future, making its market acceptance critical for profitability[151]. - The potential market opportunity for WAKIX may be smaller than estimated, with assumptions based on current market data that could prove incorrect[153]. Product Development and Pipeline - The company has exclusive rights to develop and commercialize next-generation pitolisant products, including pitolisant Gastro-Resistant and pitolisant High-Dose, currently in clinical development[18]. - The FDA granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi Syndrome (PWS) in February 2024, with a Phase 3 TEMPO study initiated in Q1 2024[33]. - The company expanded its portfolio by acquiring Epygenix Therapeutics, adding global rights to develop EPX-100 and EPX-200 for rare epilepsy, with EPX-100 in Phase 3 trials[19]. - A Phase 2 proof-of-concept trial for pitolisant in Myotonic Dystrophy Type 1 (DM1) showed clinically meaningful improvements in excessive daytime sleepiness and fatigue, with topline data released in December 2023[35]. - The company is pursuing label expansion for WAKIX in idiopathic hypersomnia, with a focus on a new formulation, pitolisant High-Dose, after receiving a refusal-to-file letter in February 2025[30]. - The company is exploring a new formulation of pitolisant for fatigue in multiple sclerosis as the lead indication, with plans for a Phase 1 PK study[38]. - Pitolisant GR and Pitolisant HD formulations entered clinical studies in Q4 2023, with a pivotal bioequivalence study for Pitolisant GR expected to submit a New Drug Application in early 2026 and a target PDUFA date in Q1 2027[37]. - The pivotal bioequivalence study confirmed that 17.8mg of Pitolisant GR is bioequivalent to existing 17.8mg WAKIX tablets, with area under the curve and Cmax ratios of 108.46% and 99.65% respectively[37]. - The total addressable market for EPX-100 among patients with Dravet Syndrome (DS) is approximately 5,000 people, and for Lennox-Gastaut Syndrome (LGS) is approximately 35,000 people[41]. - EPX-100 has been granted orphan drug designation and rare pediatric disease designation by the FDA for treatment of both DS and LGS, currently in two Phase 3 registrational clinical trials[41]. Regulatory Environment - The FDA imposes substantial regulatory requirements on the company, affecting the drug development and approval process, which requires significant time and financial resources[75]. - The FDA requires the completion of preclinical studies, including laboratory tests and animal studies, before an IND can be submitted[76]. - An IND must become effective within 30 days of submission unless the FDA raises concerns, which can delay clinical trials[76]. - Clinical trials must adhere to Good Clinical Practice (GCP) regulations, and progress reports must be submitted annually to the FDA[78]. - The FDA aims to review standard NDAs within ten months from the filing date, with a preliminary review occurring within the first 60 days[83]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of a drug outweigh its risks[84]. - The FDA inspects manufacturing facilities and clinical trial sites to ensure compliance with current Good Manufacturing Practices (cGMP) before approving an NDA[86]. - Post-approval, drugs are subject to ongoing FDA regulation, including requirements for recordkeeping and reporting adverse experiences[95]. - The FDA may withdraw approval if compliance with regulatory requirements is not maintained or if new safety issues arise post-marketing[98]. - Orphan Drug Designation allows for a seven-year marketing exclusivity period for drugs treating rare diseases affecting fewer than 200,000 individuals in the U.S.[106]. Intellectual Property and Licensing - The company relies on license agreements with Bioprojet for core intellectual property related to pitolisant, and any loss of these rights would adversely affect its business[154]. - The company has exclusive rights to develop, manufacture, and commercialize BP1.15205 in the U.S. and Latin America, with positive pre-clinical data announced in June 2025[39]. - The company has exclusive rights to develop and commercialize BP1.15205 for narcolepsy, with an upfront license fee of $25.5 million and potential milestone payments totaling up to $363.2 million[62]. - The WAKIX patent portfolio includes four U.S. patents, with expiration dates ranging from March 2030 to March 2044, ensuring protection for the product[64]. - Utility patents have been filed for Pitolisant GR and Pitolisant HD, with potential patent protection extending to the mid-2040s[37]. - The 2017 License Agreement (LCA) includes tiered royalty rates of 13% to 24% on net sales of WAKIX, with additional royalties of 3% for trademark licensing[58]. - In July 2022, the company entered into a new License Agreement (2022 LCA) with Bioprojet, paying an initial fee of $30.0 million and potential additional payments of up to $155.0 million based on milestones[60]. Market and Competitive Landscape - The U.S. narcolepsy market had an approximate net sales value of $3.1 billion in 2025, expected to grow due to new therapies and increased diagnosis rates[24]. - The company faces significant competition in securing suitable collaborators due to recent business combinations among large pharmaceutical companies, which has reduced the number of potential partners[163]. - The company competes with larger biotechnology and pharmaceutical companies that have greater resources, making it challenging to capture market share[177]. - Generic competition may lead to price decreases for branded products, impacting the commercial potential of current and future products[178]. - Negative publicity regarding pharmaceutical pricing could impact the company's reputation and market acceptance of its products, potentially affecting revenue and profitability[159]. Operational Risks - The company relies heavily on third-party collaborations for product development and commercialization, which poses risks such as limited control over resources and potential abandonment of projects by collaborators[161]. - If third-party agreements are terminated, the company may not receive expected funding, delaying the development of pitolisant and future product candidates[162]. - The company has limited manufacturing capabilities and relies on third-party manufacturers for the supply of WAKIX and product candidates, which could impact commercialization if relationships fail[172]. - The company maintains a 12-month supply of finished goods inventory to ensure product availability, but any interruption in supply could adversely affect its business[174]. - Regulatory compliance is critical, and failure by third-party manufacturers to adhere to cGMP requirements could delay the commercialization of products[176]. - Public health pandemics, such as COVID-19, have disrupted operations, affecting patient access and prescription writing[189]. - Supply chain disruptions could impact the manufacturing and shipment of WAKIX, potentially delaying clinical trials and meeting demand[189]. Human Resources and Corporate Responsibility - The company had 293 full-time employees as of December 31, 2025, with 135 in commercial functions and 103 in research and development[138]. - The company is committed to corporate social responsibility, focusing on safe working conditions and community support through monetary donations and resources[141]. - Recruiting and retaining qualified personnel in operations, finance, and clinical roles is critical, with competition from other pharmaceutical companies[185]. - The company is highly dependent on key executives and scientific teams, with potential risks if these individuals leave[183]. - Future financial performance will depend on effective management of growth activities and associated costs in hiring and training personnel[180]. Legal and Compliance Risks - Violations of healthcare laws can result in significant penalties, including fines, imprisonment, and exclusion from government healthcare programs[120]. - HIPAA imposes strict privacy and security obligations on covered entities regarding health information, with significant penalties for non-compliance[121]. - The federal Anti-Kickback Statute prohibits remuneration to induce purchases of items reimbursable under federal healthcare programs[113]. - The federal Physician Payments Sunshine Act requires manufacturers to report payments or transfers of value to physicians and teaching hospitals annually[118]. - The Prescription Drug Marketing Act regulates the distribution of prescription drugs and drug samples, ensuring accountability in distribution[100]. Data Privacy and Cybersecurity - The company faces cybersecurity risks due to increased reliance on information technology systems and remote work[194]. - The rapid evolution of artificial intelligence presents risks related to data privacy, cybersecurity, and regulatory compliance[197]. - The U.S. regulatory environment for artificial intelligence is complex, with state and federal laws creating a challenging landscape[200]. - The integration of AI systems may increase cybersecurity risks and create new vulnerabilities for the company and its vendors[201]. Financial Obligations and Credit Risks - The company faces significant payment obligations under licensing agreements, which could impact its ability to develop and market products if not met[209][210]. - The TLA Credit Agreement contains restrictive covenants that may limit the company's operational flexibility and ability to engage in certain transactions[211]. - Failure to comply with the TLA Credit Agreement could result in default, leading to accelerated repayment obligations that may adversely affect financial condition[212][213]. - The company's obligations under the TLA Credit Agreement are secured by all assets, which could impact the distribution of assets in a liquidation scenario[214]. - The company has never paid dividends on common stock and does not intend to do so in the foreseeable future, relying on stock price appreciation for investor returns[215].

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over- year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its. ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, but identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Company Overview - Harmony Biosciences Holdings, Inc. (HRMY) is highlighted as a recommended growth stock based on the Zacks Growth Style Score, which evaluates a company's genuine growth prospects beyond traditional metrics [2] - The company has a favorable Growth Score and a top Zacks Rank, indicating strong investment potential [2] Group 2: Earnings Growth - Harmony Biosciences has a historical EPS growth rate of 13.1%, but the projected EPS growth for this year is significantly higher at 26.7%, surpassing the industry average of 13.7% [4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Harmony Biosciences is currently at 10%, which is notably higher than the industry average of -3.1% [5] - Over the past 3-5 years, the company's annualized cash flow growth rate has been 25.7%, compared to the industry average of 4.4% [6] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Harmony Biosciences have been revised upward, with the Zacks Consensus Estimate increasing by 7.4% over the past month, indicating a positive trend in earnings estimate revisions [7] Group 5: Investment Positioning - Harmony Biosciences has achieved a Zacks Rank 1 (Strong Buy) and a Growth Score of B, positioning the company well for potential outperformance in the market, making it an attractive option for growth investors [9]